Compare Regeneron Pharmaceuticals Inc (REGN) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Sirius XM Holdings Inc trades at $29.82 (market cap $10.20B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.9× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| REGN | SIRI | |
|---|---|---|
Market Cap | $70.79B | $10.20B |
Sector | Health | Media |
52-Week High | $812.27 | $31.22 |
52-Week Low | $545.46 | $19.92 |
Enterprise Value | $64.74B | $19.87B |
Dividend Yield | 0.56% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Sirius XM (SIRI) trades at $30.29, down 0.98% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 12.97, net income margin of 9.86%, and a recent dividend payment. Revenue stabilized around $8.6B in 2025 after a dip in 2024, while debt-to-asset ratio improved to 35.63%.
Outlook is positive with analyst consensus at Buy (58% of ratings) and a $30.71 price target, though risks include competitive pressures and reliance on subscription growth. The YouTube ad partnership and inclusion in the S&P MidCap 400 provide catalysts, but investors should monitor Q2 2026 earnings due July 30 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
